A combination of therapies may prove to be a promising advance for the treatment of anaplastic thyroid cancer based on results of a phase I clinical trial, say researchers. Anaplastic thyroid cancer is one of the deadliest of all cancers. Nearly all patients diagnosed with this cancer die from it, and life expectancies are measured in weeks to a few months.